NCT07033598View on ClinicalTrials.gov

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2028

Conditions
Leukemia, Myelomonocytic, Chronic
Interventions
DRUG

Pacritinib

100-mg capsules

DRUG

Hydroxyurea

capsules or tablets

Sponsors

Lead Sponsor

Theradex
All Listed Sponsors
collaborator

Sobi, Inc.

INDUSTRY

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

Theradex

INDUSTRY